{"id":1068500,"date":"2024-03-18T02:36:26","date_gmt":"2024-03-18T06:36:26","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/new-positive-data-presented-on-briquilimab-conditioning-in-patients-with-fanconi-anemia\/"},"modified":"2024-08-18T11:48:01","modified_gmt":"2024-08-18T15:48:01","slug":"new-positive-data-presented-on-briquilimab-conditioning-in-patients-with-fanconi-anemia","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/new-positive-data-presented-on-briquilimab-conditioning-in-patients-with-fanconi-anemia.php","title":{"rendered":"New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia"},"content":{"rendered":"<p><![CDATA[REDWOOD CITY, Calif., March  15, 2024  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive Phase 1b\/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA).]]><\/p>\n<p>Continued here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/03\/15\/2847004\/0\/en\/New-Positive-Data-Presented-on-Briquilimab-Conditioning-in-Patients-with-Fanconi-Anemia.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia\">New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Continued here: New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/new-positive-data-presented-on-briquilimab-conditioning-in-patients-with-fanconi-anemia.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068500","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068500"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068500"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068500\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}